Perioperative Cost Comparison between Percutaneous Microwave Ablation and Partial Nephrectomy for Localized Renal

Clinton Yeaman1, Lauren O'Connor2, Jennifer Lobo2

  • 1Department of Urology, University of Virginia, Charlottesville, Virginia.

Urology Practice
|May 5, 2023
PubMed
Abstract

Insights

Percutaneous microwave ablation (MWA) is significantly less expensive than robot-assisted partial nephrectomy (RA-PN) for localized renal masses. MWA also shows lower complication costs, making it a more cost-effective treatment option.

Area of Science:

  • Urology
  • Minimally Invasive Surgery
  • Health Economics

Background:

  • Localized renal masses (LRMs) require effective treatment strategies.
  • Perioperative costs of different LRM treatments vary significantly.
  • Comparing percutaneous microwave ablation (MWA) and robot-assisted partial nephrectomy (RA-PN) is crucial for cost-effective patient care.

Purpose of the Study:

  • To determine and compare the perioperative costs of MWA versus RA-PN for treating LRMs.
  • To analyze the cost implications of complications associated with each procedure.

Main Methods:

  • Retrospective cohort analysis of a prospectively maintained LRM database (2015-2020).
  • Inclusion of patients treated with MWA or RA-PN.
  • Calculation of allocated costs using cost-to-charges methodology, including medical center and physician costs.

Main Results:

  • A total of 279 patients (165 MWA, 114 RA-PN) were analyzed.
  • Mean total perioperative cost was significantly lower for MWA ($6,470) compared to RA-PN ($20,536) (p <0.0001).
  • Complication rates were similar (3% MWA, 6% RA-PN), but RA-PN had significantly higher costs associated with major complications (p=0.008).

Conclusions:

  • Percutaneous microwave ablation (MWA) demonstrates substantially lower perioperative costs than robot-assisted partial nephrectomy (RA-PN) for LRM treatment.
  • MWA also incurs lower costs related to complications.
  • Updated cost data supports MWA as a more cost-effective option, warranting further cost-effectiveness studies.